Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2014-01-08 | adeno-associated viral vector containing the human NADH dehydrogenase 4 gene | Gensight-Biologics (France) | Leber's hereditary optic neuropathy (LHON) | Granting of the orphan status in the EU |
2014-01-09 | 40K PEGylated recombinant factor IX | Novo Nordisk (Denmark) | routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease) | |
2014-01-09 | elafin | Proteo Biotech (Germany) | prevention of inflammatory complications of transthoracic esophagectomy |
|
2017-08-17 | inotuzumab ozogamicin | Pfizer (USA - NY) | relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia | Granting of a Market Authorisation in the US |
2014-01-10 | denileukin diftitox | Eisai (Japan) | ||
2015-06-29 | ibrutinib | Pharmacyclics (USA - CA), now Abbvie (USA - IL) - Janssen-Cilag International, a J&J company (USA - NJ) | Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma) | Granting of a Market Authorisation in the EU |
2013-05-30 | ibrutinib | Pharmacyclics (USA - CA) | small lymphocytic lymphoma |
Granting of the orphan status in the US |
2013-05-16 | ibrutinib | Pharmacyclics (USA - CA) | multiple myeloma |
Granting of the orphan status in the US |
2014-01-13 | small-molecule prodrug of monomethyl fumarate | Alkermes (Ireland) | multiple sclerosis |
Granting of a patent |
2015-09-10 | daclatasvir | BMS (USA) | treatment of adults with chronic hepatitis C (HCV) with compensated liver disease, including genotypes 1, 2, 3, and 4 |
Granting of a Market Authorisation in the EU |
2014-01-14 | human plasmin | Grifols (Spain) | acute peripheral arterial occlusion | |
2014-01-15 | (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol | Voisin Consulting (France) | acute myeloid leukaemia |
Granting of the orphan status in the EU |
2014-01-15 | (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol | Voisin Consulting (France) | acute lymphoblastic leukaemia |
Granting of a patent |
2014-01-15 | adenovirus-specific T-cells derived from allogeneic donor leukocytes, expanded ex vivo | Cell Medica (UK) | adenovirus infection in allogeneic haematopoietic stem cell transplant recipients |
Granting of a patent |
2014-01-16 | allantoin | ORS Oxford (UK) | epidermolysis bullosa |
Granting of the orphan status in the EU |
2014-01-16 | allogeneic bone-marrow derived adherent ex-vivo expanded multipotent adult progenitor cell | ReGenesys (Belgium) | prevention of graft-versus-host disease |
Granting of the orphan status in the EU |
2014-05-06 | autologous dendritic cells pulsed with allogeneic tumour cell lysate | Amphera (The Netherlands) | malignant mesothelioma |
Granting of the orphan status in the US |
2014-04-20 | lonafarnib | Eiger Biopharmaceuticals (USA - CA) | hepatitis delta virus infection |
Granting of a Fast Track status |
2017-05-25 | obeticholic acid in combination with ursodeoxycholic (UDCA) | Intercept Pharmaceuticals (USA - NY) | primary sclerosing cholangitis/primary biliary cirrhosis | Granting of a Market Authorisation in Canada |
2014-01-15 | sodium nitrite | Hope Pharmaceuticals (USA) | aneurysmal subarachnoid haemorrhage |
© 2024 Biopharmanalyses - Powered by Samacom+